Papers/PMID:34193235
Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study.
Critical care (London, England)2021The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
thiamine — decreases all-cause mortality
ModerateEvidence strength: moderate. Human evidence with one recorded weakness, or capped at moderate by its design or by unread numbers.Findingreplicated ×9“In other words, patients who received thiamine as adjunctive therapy during ICU stay had a lower 30-day mortality rate by 63% [OR (95% CI): 0.37 (0.18, 0.78), P value = 0.009] (Table 1).”
Quoted verbatim from Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study.. - Study
- cohort
- Population
- Critically ill adults with COVID-19 in two ICUs, retrospective cohort; adjunctive thiamine versus none, propensity-score matched (83 pairs); horizon is 30 days
Effect 0.37 odds ratio, 95% CI 0.18 to 0.78
Evaluation of thiamine as adjunctive therapy in COVID-19 critically ill patients: a two-center propensity score matched study.2021PMID:34193235Permalink